Business Context and Reporting Period
Company: Innovative Industrial Properties, Inc. (IIPR)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: IIPR is an internally-managed REIT focused on acquiring, owning, and managing specialized industrial and commercial properties primarily leased to state-licensed regulated cannabis operators. The company also expanded into life science investments in 2025. As of year-end, the portfolio consisted of 111 properties (8.9 million rentable square feet) across 19 states, with 109 properties in the operating portfolio leased at 96.7%.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Rental Revenues | $265.5 million | $306.9 million | (14)% |
| Net Income (Common Stockholders) | $114.4 million | $159.9 million | (28)% |
| Diluted EPS | $3.93 | $5.52 | (29)% |
| AFFO (Common Stockholders) | $205.4 million | $256.1 million | (20)% |
| AFFO per Share (Diluted) | $7.24 | $8.98 | (19)% |
| Dividends Declared (Common) | $7.60 per share | $7.52 per share | 1% |
| Total Debt Outstanding | $468.7 million | $291.2 million* | N/A |
| Cash and Equivalents | $47.6 million | $146.2 million | (67)% |
*2024 debt figure reflects only Notes due 2026; 2025 includes new credit facilities.
Material Changes vs. Prior Period
- Revenue Decline: Rental revenues decreased by $41.5 million (14%) primarily due to tenant defaults (PharmaCann, Gold Flora, TILT, 4Front) totaling $46.9 million in lost rent. This was partially offset by $16.5 million in growth from new acquisitions, leases, and contractual escalations.
- Life Science Expansion: The company launched a new "Life Science Portfolio" segment, investing $150.3 million in financial instruments related to IQHQ, Inc., including a $100 million credit facility and $50 million in preferred stock. This generated $5.0 million in interest and dividend income.
- Debt Structure: While the $291.2 million Notes due 2026 remain outstanding, the company added $102.5 million in borrowings across two new revolving credit facilities (Revolving Credit Facility and IIP Life Science Credit Facility) to fund operations and life science investments.
- Impairments and Sales: Recognized a $3.5 million impairment loss on a Palm Springs property and a $0.3 million loss on the sale of a Mancos, Colorado property. A Michigan property sale did not qualify for GAAP sale recognition, remaining on the balance sheet.
Guidance, Outlook, Risks, and Contingencies
- Going Concern Warning: The independent auditor's report includes an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern. This is due to the maturity of $291.2 million in Notes due 2026 in May 2026, which the company currently lacks sufficient liquidity to repay without refinancing or additional capital.
- Tenant Defaults: Significant defaults continue to impact the portfolio. PharmaCann defaulted on nine leases ($29.2 million due), and the company declared defaults on 4Front, Gold Flora, and TILT. The company is actively pursuing evictions and litigation.
- Regulatory Risks: Cannabis remains illegal under federal law. The company faces risks related to federal enforcement, banking restrictions, and Section 280E tax disallowances for tenants. An SEC investigation was initiated in February 2026 regarding matters similar to pending securities class action lawsuits.
- Capital Commitments: The company has a remaining commitment of $120 million to purchase IQHQ Preferred Stock, scheduled to be funded through mid-2027, and $6.5 million in tenant improvement allowances.
Investor Verification Checklist
- Debt Refinancing Status: Verify if the company has secured a refinancing plan or extension for the $291.2 million Notes due 2026 maturing in May 2026.
- Tenant Recovery: Monitor the status of eviction proceedings and re-leasing efforts for properties vacated by PharmaCann, 4Front, and Gold Flora.
- SEC Investigation: Track developments regarding the SEC investigation and pending securities class action lawsuits filed in 2025.
- Liquidity Position: Assess the company's ability to fund the remaining $120 million IQHQ commitment while maintaining dividend payments and servicing new debt.
- Life Science Investment Performance: Evaluate the credit quality and performance of the IQHQ Credit Facility and Preferred Stock investments.